Solara Active Pharma spurts after reporting turnaround Q4 perfromance
Mumbai, May 15 -- Revenue from operations jumped 41.86% to Rs 387.29 crore in Q4 FY26.
The company reported a profit before exceptional items and tax of Rs 8.74 crore in Q4 FY26 compared with a loss before exceptional items and tax of Rs 2.10 crore in Q4 FY25. It reported exceptional gain of Rs 0.86 crore during the quarter.
EBITDA increased 21% to Rs 61.7 crore in Q4 FY26, compared with Rs 51 crore in Q4 FY25. EBITDA margin redcued to 15.8% in Q4 FY26 compared with 18.3% in Q4 FY25.
During the quarter, revenue from base business jumped 36% YoY to Rs 307 crore while revenue from Ibuprofen business climbed 61% YoY to Rs 849 crore.
On full year basis, the company reported consolidated net loss of Rs 7.41 crore in FY26 compared with net ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.